Harmony Biosciences
HRMY | NASDAQ
$32.96
-$0.80 (-2.37%)
At close: Nov 16, 2026, 4:00 PM ET
$32.96
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Harmony Biosciences Company Profile
Company profile explainedCompany Profile
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Jeffrey Dayno | President, Chief Executive Officer & Director |
| Peter Anastasiou | Chief Operating Officer |
| Adam Zaeske | Executive Vice President & Chief Commercial Officer |
| Andrew Serafin | Executive Vice President & Chief Strategy Officer |
| Audrey Murphy | Chief Human Resources Officer |
| Brennan Doyle | Vice President & Head of Investor Relations |
| Christian Ulrich | Executive VP, General Counsel & Corporate Secretary |
| Jeffrey S. Aronin | Founder & Non-Executive Chairman |
| Kumar Budur | Executive Vice President and Chief Medical & Scientific Officer |
| Stephen Mollichella | Senior VP, Controller & Interim Principal Financial Officer |
| Tricia Glover | Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 8-K/A | [Amend] Current Report |
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 13, 2026 | 8-K | Current Report |
| Sep 18, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Aug 04, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 31, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 22, 2026 | 3 | Filing |
Harmony Biosciences
| Country | United States |
| IPO Date | Aug 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 293 |
| CEO | Jeffrey Dayno |
Contact Details
630 West Germantown Pike Plymouth Meeting,
Pennsylvania 19462 United States
Stock Details
| Ticker Symbol | HRMY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001802665 |
| CUSIP Number | 413197104 |
| ISIN Number | US4131971040 |
| SIC Code | 2834 |
Recent News
- 11 days ago / zacks.comHRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
- 12 days ago / seekingalpha.comHarmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript
- 13 days ago / marketbeat.comHarmony Biosciences Q3 Earnings Call Highlights
- 13 days ago / zacks.comHarmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates
- 20 days ago / zacks.comHarmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
- 26 days ago / zacks.comHRMY or ARGX: Which Is the Better Value Stock Right Now?
- 26 days ago / zacks.comAre Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
- 26 days ago / barrons.comRevisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences
- 27 days ago / seekingalpha.comHarmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It
- 28 days ago / globenewswire.comHarmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Add to Watchlist
Select watchlists to add or remove HRMY